StockScan › Stocks › NTLA
Biotechnology
NTLA
106.92
  Price7.03%   -8.09
(Pre-market: .00 -106.92 -100.00%)
KEY STATS
Previous Close:
$115.01
Market Cap:
$7.96B
24h Volume:
977.40K
1D Range:
$106.90 - $117.70
52W Range:
$37.00 - $202.73
Primary Exchange:
COMPANY PROFILE
NameNameIntellia Therapeutics
SectorHealthcare (1214)
IndustryBiotechnology (721)
Webintelliatx.com
Phone857-285-6200
Employee195
Twitter @intelliatweets
Latest SEC Filings
NTLA's Discussions on Twitter
40 Erie Street, Suite 130, Cambridge, MA, United States (2139)
News Options Financials Holders Transactions Discussions Predictions
Nov-22-21 07:30AM Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)GlobeNewswire Inc.
Nov-21-21 11:31AM Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?The Motley Fool
Nov-06-21 12:30PM Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call TranscriptThe Motley Fool
Nov-05-21 07:30AM Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual MeetingGlobeNewswire Inc.
Nov-04-21 08:55AM Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research
08:14AM The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPOBenzinga
Nov-04-21 07:30AM Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc.
06:20AM Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?Zacks Investment Research
Oct-22-21 07:05AM Biotech Buyouts That Would Be Great for InvestorsThe Motley Fool
Oct-21-21 09:25AM If I Could Only Own 1 Healthcare Stock, This Is What It Would BeThe Motley Fool
07:30AM Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisGlobeNewswire Inc.
Oct-21-21 06:20AM Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?Zacks Investment Research
Oct-20-21 07:30AM Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual CongressGlobeNewswire Inc.
Oct-17-21 09:01AM 2 Gene-Editing Stocks to Have on Your Radar Right NowThe Motley Fool
Oct-08-21 07:31AM The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOsBenzinga
Sep-30-21 10:37AM Editas (EDIT) Down on Initial Data From Eye Disease StudyZacks Investment Research
Sep-27-21 07:30AM Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines ConferenceGlobeNewswire Inc.
Sep-23-21 05:55AM Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling AnotherThe Motley Fool
Sep-16-21 07:30AM Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid LeukemiaGlobeNewswire Inc.
Sep-09-21 12:37PM 3 Red-Hot Healthcare Stocks to Buy in SeptemberThe Motley Fool
Sep-07-21 09:10AM 3 Hot Stocks to Buy in SeptemberThe Motley Fool
Sep-03-21 12:55PM Intellia's Bold Bet Pays Off, Justifying Its ValuationSeeking Alpha
Aug-31-21 07:30AM Intellia Therapeutics to Present at September Healthcare Investor ConferencesGlobeNewswire Inc.
Aug-24-21 10:56AM New Strong Sell Stocks for August 24thZacks Investment Research
Aug-17-21 10:21AM Editas (EDIT) Up More Than 70% in Past 3 Months: Here's WhyZacks Investment Research
Aug-14-21 08:00AM How Are Genomics ETFs Responding to Q2 Earnings?Zacks Investment Research
Aug-12-21 05:52AM Will Moderna Buy Editas Medicine to Jump Into Gene Editing?The Motley Fool
Aug-06-21 08:01AM Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call TranscriptThe Motley Fool
09:15AM S&P, NASDAQ Set New Highs While Waiting for Jobs ReportZacks Investment Research
Aug-05-21 03:59AM Why Shares of Intellia Therapeutics Are Jumping TodayThe Motley Fool
08:45AM Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research
Aug-05-21 07:30AM Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewswire Inc.
Aug-04-21 07:52AM The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On EarningsBenzinga
Aug-02-21 08:52AM Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?Zacks Investment Research
Aug-01-21 10:13AM The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOsBenzinga
Jul-30-21 06:35AM 3 Things About Illumina That Smart Investors KnowThe Motley Fool
Jul-29-21 03:05AM Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research
07:30AM Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company UpdatesGlobeNewswire Inc.
Jul-29-21 05:23AM 3 Things About Regeneron That Smart Investors KnowThe Motley Fool
Jul-27-21 12:45PM 3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your PortfolioThe Motley Fool
Jul-21-21 11:49AM Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?Benzinga
Jul-16-21 11:02AM Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This WeekThe Motley Fool
Jul-15-21 08:19AM After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are ExplodingThe Motley Fool
Jul-13-21 08:09AM Wall Street Breakfast: Ring The Register? (Podcast)Seeking Alpha
07:13AM Wall Street Breakfast: Ring The Register?Seeking Alpha
Jul-12-21 03:12AM WHO Issues Framework For Governance For Gene Editing TechnologiesBenzinga
Jul-11-21 07:01AM Intellia Therapeutics' Next Hurdles After Its Positive Clinical ResultsThe Motley Fool
06:43AM 3 Top Biotech Stocks to Buy in JulyThe Motley Fool
Jul-10-21 06:12AM Where Will ARK Genomic Revolution ETF Be in 5 Years?The Motley Fool
05:19AM Is It Too Late to Buy Intellia Therapeutics?The Motley Fool
About Intellia Therapeutics
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
List of SPAC Stocks List of EV Stocks and Related Stocks Top 100 popular stocks on Robinhood List of Marijuana Stocks
Open in Yahoo | Open in Google | Open in Finviz
Cap:    |  Volume (24h):